BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview
NASDAQ:BDTX • US09203E1055
Current stock price
The current stock price of BDTX is 3.05 USD. Today BDTX is down by -0.33%. In the past month the price increased by 44.55%. In the past year, price increased by 91.82%.
BDTX Key Statistics
- Market Cap
- 174.735M
- P/E
- 8.24
- Fwd P/E
- N/A
- EPS (TTM)
- 0.37
- Dividend Yield
- N/A
BDTX Stock Performance
BDTX Stock Chart
BDTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BDTX. When comparing the yearly performance of all stocks, BDTX is one of the better performing stocks in the market, outperforming 90.64% of all stocks.
BDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BDTX. BDTX has an excellent financial health rating, but there are some minor concerns on its profitability.
BDTX Earnings
BDTX Forecast & Estimates
15 analysts have analysed BDTX and the average price target is 9.91 USD. This implies a price increase of 224.87% is expected in the next year compared to the current price of 3.05.
For the next year, analysts expect an EPS growth of -275.09% and a revenue growth -100% for BDTX
BDTX Groups
Sector & Classification
BDTX Financial Highlights
Over the last trailing twelve months BDTX reported a non-GAAP Earnings per Share(EPS) of 0.37. The EPS increased by 129.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.95% | ||
| ROA | 15.64% | ||
| ROE | 19.93% | ||
| Debt/Equity | 0 |
BDTX Ownership
BDTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.74 | 360.314B | ||
| AMGN | AMGEN INC | 15.33 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.99 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.55 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.37 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BDTX
Company Profile
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Company Info
IPO: 2020-01-30
BLACK DIAMOND THERAPEUTICS I
245 First Street, 18Th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: David M. Epstein
Employees: 21
Phone: 16174175868
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
Can you describe the business of BLACK DIAMOND THERAPEUTICS I?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
What is the current price of BDTX stock?
The current stock price of BDTX is 3.05 USD. The price decreased by -0.33% in the last trading session.
Does BDTX stock pay dividends?
BDTX does not pay a dividend.
How is the ChartMill rating for BLACK DIAMOND THERAPEUTICS I?
BDTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the upcoming earnings date for BLACK DIAMOND THERAPEUTICS I?
BLACK DIAMOND THERAPEUTICS I (BDTX) will report earnings on 2026-05-13.
Can you provide the ownership details for BDTX stock?
You can find the ownership structure of BLACK DIAMOND THERAPEUTICS I (BDTX) on the Ownership tab.